

Walgreens Boots Alliance Fiscal 2020 and Q4 Results

We expect EPS growth in fiscal 2021

“Now, more than ever, our pharmacy-centered business is at the heart of community healthcare and we are expanding on that role for the future. I continue to be inspired by the tireless efforts of our teams as they support and care for our customers, patients and communities, while accelerating progress on our clear set of strategic priorities.”

Executive Vice Chairman and CEO Stefano Pessina

Selected Financial Results

For complete Q4 and fiscal 2020 results, announced on Oct. 15, 2020, please [click here](#).

Sales

\$139.5B

in fiscal 2020, up 2.0% year-on-year

Adjusted EPS

\$4.74

in fiscal 2020, down 20.8% year-on-year

Free cash flow

\$4.1B

in fiscal 2020, up 5.6% year-on-year

Reported EPS

\$0.52

in fiscal 2020, down 88.0% year-on-year

COVID Impact

- Despite uncertainty due to the global pandemic, we saw gradual improvement in key U.S. and UK markets in Q4
- The estimated impact of COVID-19 on fiscal 2020 adjusted operating income was approximately \$1.2 billion




Outlook

Our fiscal 2021 guidance is for low single-digit growth in adjusted EPS at constant currency rates. This anticipates a continued gradual reduction in COVID-19 impacts, but the evolution of the pandemic is uncertain.

Strategic Priorities



**Creating
Neighborhood
Health Destinations**



**Transforming and
Restructuring Our
Retail Offering**



**Accelerating
Digitalization**



**Driving the
Transformational
Cost Management
Program**

Business Updates

myWalgreens

Launching enhanced customer loyalty program myWalgreens to more than 100 million consumers and expanding convenient options for pick-up in as little as 30 minutes




Retail Pharmacy USA Division

Prescription volume in comparable stores rose **3.6%** in Q4 from a year earlier

Digital sales


Boots.com sales rose **155%** in Q4 vs. year ago

Walgreens.com sales rose **39%** in Q4 vs. year ago



Mass personalization boosted Walgreens retail sales by **1.4** percentage points in Q4

Transformational Cost Management Program on track for **\$2B+/year** cost savings by FY22



Walgreens and DoorDash announce on-demand delivery

Walgreens and VillageMD to open **500-700** full-service doctor offices over next five years

GuoDa footprint in China expands to **7,500+** pharmacies, nearly double from the start of WBA-GuoDa relationship in 2018



Find Care visits up **184%** from Q3, to **8.5M**

COVID-19 Response

1M+
tests

conducted at Walgreens sites as of September

444
testing sites

in 49 states

500k
tests per month

current Walgreens capacity

70%+
of testing sites

located in underserved areas

Testing
for businesses

program launched

1M+
tests

completed by Boots UK for NHS

This message contains selected results from WBA's fiscal quarter and year ended August 31, 2020 and is not intended to be a substitute for a comprehensive review of the company's earnings release, linked above and available in the Investor Relations section of walgreensbootsalliance.com, and the company's filings with the U.S. Securities and Exchange Commission, which can be found at www.SEC.gov.

Cautionary Note Regarding Forward-Looking Statements: All statements in this message that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially and speak only as of the date they are made. We do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this message.

WBA reports earnings according to generally accepted accounting principles (GAAP). The company's adjusted results are non-GAAP financial measures that exclude the impact of certain items affecting comparability and which supplement GAAP results. Please refer to the "Supplemental Information (Unaudited) Regarding Non-GAAP Financial Measures" in the press release for more information including reconciliations to the most directly comparable GAAP financial measures.

Free cash flow is a non-GAAP financial measure. WBA net cash provided by operating activities was \$5.5 billion in fiscal 2020, down \$109 million from fiscal 2019.